|
Cholestasis, Extrahepatic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hepatoprotective effects of diosmin and/or sildenafil against cholestatic liver cirrhosis: The role of Keap-1/Nrf-2 and P38-MAPK/NF-κB/iNOS signaling pathway.
|
30026087 |
2018 |
|
Primary biliary cirrhosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hepatoprotective effects of diosmin and/or sildenafil against cholestatic liver cirrhosis: The role of Keap-1/Nrf-2 and P38-MAPK/NF-κB/iNOS signaling pathway.
|
30026087 |
2018 |
|
Hepatomegaly
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Hepatoprotective effects of diosmin and/or sildenafil against cholestatic liver cirrhosis: The role of Keap-1/Nrf-2 and P38-MAPK/NF-κB/iNOS signaling pathway.
|
30026087 |
2018 |
|
Biliary cirrhosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hepatoprotective effects of diosmin and/or sildenafil against cholestatic liver cirrhosis: The role of Keap-1/Nrf-2 and P38-MAPK/NF-κB/iNOS signaling pathway.
|
30026087 |
2018 |
|
Secondary Biliary Cholangitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hepatoprotective effects of diosmin and/or sildenafil against cholestatic liver cirrhosis: The role of Keap-1/Nrf-2 and P38-MAPK/NF-κB/iNOS signaling pathway.
|
30026087 |
2018 |
|
Hepatic Insufficiency
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Hepatoprotective effects of diosmin and/or sildenafil against cholestatic liver cirrhosis: The role of Keap-1/Nrf-2 and P38-MAPK/NF-κB/iNOS signaling pathway.
|
30026087 |
2018 |
|
Biliary Cirrhosis, Primary, 1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Hepatoprotective effects of diosmin and/or sildenafil against cholestatic liver cirrhosis: The role of Keap-1/Nrf-2 and P38-MAPK/NF-κB/iNOS signaling pathway.
|
30026087 |
2018 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Cytoglobin overexpression protects against damage-induced fibrosis.
|
16581302 |
2006 |
|
Heredodegenerative Disorders, Nervous System
|
0.300 |
Biomarker
|
group |
CTD_human |
p53-mediated apoptosis, neuroglobin overexpression, and globin deposits in a patient with hereditary ferritinopathy.
|
16825958 |
2006 |
|
Renal fibrosis
|
0.220 |
Biomarker
|
disease |
BEFREE |
Several antioxidant and renoprotective agents, including cysteamine bitartrate, epoxyeicosatrienoic acids (EETs), and cytoglobin (Cygb) have demonstrated ameliorative effects on renal fibrosis in preclinical or clinical studies.
|
29503620 |
2018 |
|
Renal fibrosis
|
0.220 |
AlteredExpression
|
disease |
BEFREE |
In vitro studies revealed that overexpression of cytoglobin suppressed phosphorylation of Smad2, ERK, and p38 induced by TGF-β and expression of NF-kB, α-SMA, and TGF-β RI.LDP prevented renal fibrosis and protected glomerular mesangial cells by upregulation of cytoglobin and suppression of multiple pathways involving TGF-β/SMADS, MAPK, NF-kB signaling.
|
28099346 |
2017 |
|
Renal fibrosis
|
0.220 |
Therapeutic
|
disease |
RGD |
To clarify the role of Cygb in kidney fibrosis, we employed the remnant kidney model in rats.
|
20719976 |
2010 |
|
Liver Cirrhosis
|
0.210 |
Biomarker
|
disease |
BEFREE |
Targeting Keap-1/Nrf-2 pathway and cytoglobin as a potential protective mechanism of diosmin and pentoxifylline against cholestatic liver cirrhosis.
|
29852187 |
2018 |
|
Liver Cirrhosis
|
0.210 |
Biomarker
|
disease |
RGD |
Cytoglobin overexpression protects against damage-induced fibrosis.
|
16581302 |
2006 |
|
Liver Cirrhosis
|
0.210 |
Biomarker
|
disease |
RGD |
Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells.
|
11320098 |
2001 |
|
Kidney Diseases
|
0.200 |
Biomarker
|
group |
RGD |
Cytoglobin/STAP, its unique localization in splanchnic fibroblast-like cells and function in organ fibrogenesis.
|
14647402 |
2004 |
|
Pancreatitis, Chronic
|
0.200 |
Biomarker
|
disease |
RGD |
Cytoglobin/STAP, its unique localization in splanchnic fibroblast-like cells and function in organ fibrogenesis.
|
14647402 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We previously demonstrated that 5F 203 induced the expression of putative tumor suppressor gene cytoglobin (CYGB) in breast cancer cells.
|
30450577 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, this study demonstrated that cytoglobin functions as a tumor suppressor and targets CSCs at an ONS-dependent manner.
|
30365183 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CYGB could be a promising candidate for further studies as a potential target for diseases related to cell migration such as cancer and chronic wound treatment.
|
28620820 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies suggested the globin family member cytoglobin (CYGB) as a potential tumor suppressor; however, the mechanism by which CYGB suppresses cancer is elusive.
|
30545372 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ectopic CYGB expression suppressed proliferation, migration, invasion and induced apoptosis in breast cancer cell lines MCF7 (p53WT) and MB231 (p53mt) in vitro, and inhibited xenograft tumor growth in vivo.
|
30545372 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Microarray analysis indicated that CYGB overexpression leads to downregulation of cell proliferation, migration, and tumor growth associated genes in L929 cell line.
|
28620820 |
2018 |
|
Microalbuminuria
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A variant within the FTO confers susceptibility to diabetic nephropathy in Japanese patients with type 2 diabetes.
|
30566433 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
CYGB could be a promising candidate for further studies as a potential target for diseases related to cell migration such as cancer and chronic wound treatment.
|
28620820 |
2018 |